This trial evaluates aldafermin, a potential treatment for cirrhosis, in a group of patients with the disease. The study is double-blind, meaning that neither the patients nor the researchers know who is receiving the active drug or the placebo.
3 Primary · 0 Secondary · Reporting Duration: 48 weeks
Experimental Treatment
Non-Treatment Group
160 Total Participants · 4 Treatment Groups
Primary Treatment: aldafermin · Has Placebo Group · Phase 2
Age 18 - 75 · All Participants · 3 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:| Ohio | 100.0% |
| Did not meet criteria | 100.0% |
| 0 | 100.0% |